Please use this identifier to cite or link to this item: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/10493
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNalband, Saifen_US
dc.contributor.authorKIRATKAR, PALLAVIen_US
dc.contributor.authorGupta, Mauliken_US
dc.contributor.authorGambhir, Mansien_US
dc.contributor.authorSonam, Surabhien_US
dc.contributor.authorRobert, Femien_US
dc.contributor.authorPrince, A. Amalinen_US
dc.date.accessioned2025-10-31T04:50:00Z-
dc.date.available2025-10-31T04:50:00Z-
dc.date.issued2025-10en_US
dc.identifier.citationBMC Medical Informatics and Decision Making, 25, 378.en_US
dc.identifier.issn1472-6947en_US
dc.identifier.urihttps://doi.org/10.1186/s12911-025-03041-4en_US
dc.identifier.urihttp://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/10493-
dc.description.abstractBackground: Leishmaniasis, a neglected tropical disease caused by Leishmania protozoan parasites and transmitted by sandflies, poses a significant global health challenge, especially in resource-limited environments. The life cycle of the parasite includes crucial amastigote and promastigote stages, each contributing importantly to the infection process. The current therapies for leishmaniasis face limitations due to considerable side effects and the rise of drug-resistant strains, underscoring the pressing need for new, effective, and safe treatment options. Recent advancements in leishmaniasis vaccine development include live attenuated vaccines, recombinant vaccines, and the use of synthetic biology. These approaches aim to induce robust immune responses while ensuring safety. Controlled human infection studies are also being explored to accelerate vaccine development. However, a licensed vaccine remains elusive. Method: This study introduces a novel method for drug discovery targeting leishmaniasis, employing machine learning and cheminformatics to forecast the efficacy of compounds against Leishmania promastigotes. A detailed dataset consisting of 65,057 molecules sourced from the PubChem database is utilized, with the Alamar Blue-based assay applied to assess drug susceptibility. The data encoding relies on molecular fingerprints derived from Simplified Molecular Input Line Entry System (SMILES) notations. We employed three distinct fingerprint algorithms, Avalon, MACCS Key, and Pharmacophore, for the development of machine learning models. Various algorithms, including random forest, multilayer perceptron, gradient boosting, and decision tree, are utilized to create models that effectively classify molecules as either active or inactive based on their structural and chemical characteristics, which could significantly impact the drug discovery process for leishmaniasis. Results: We additionally introduced a model based on ensembles, achieving a peak accuracy of 83.65% and an area under the curve of 0.8367. This study offers significant promise in enhancing drug discovery efforts focused on tackling the global issue of leishmaniasis. Conclusion: Furthermore, the proposed approach has the potential to serve as a framework for addressing other overlooked tropical diseases, offering a promising alternative to conventional drug discovery methods and their associated difficultieen_US
dc.language.isoenen_US
dc.publisherBioMed Central Ltden_US
dc.subjectLeishmananiaen_US
dc.subjectMachine learningen_US
dc.subjectMolecular fingerprintsen_US
dc.subjectEnsemble learningen_US
dc.subject2025-OCT-WEEK4en_US
dc.subjectTOC-OCT-2025en_US
dc.subject2025en_US
dc.titleEnsemble techniques for predictive modeling of leishmanial activity via molecular fingerprintsen_US
dc.typeArticleen_US
dc.contributor.departmentDept. of Biologyen_US
dc.identifier.sourcetitleBMC Medical Informatics and Decision Makingen_US
dc.publication.originofpublisherForeignen_US
Appears in Collections:JOURNAL ARTICLES

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.